Latest News

Grupo Aeroméxico, S.A.B. de C.V. ( NYSE:AERO ) shareholders are probably feeling a little disappointed, since its...

The UK market has faced challenges recently, with the FTSE 100 and FTSE 250 indices closing lower due to weak trade data from China, highlighting concerns about global economic recovery. Despite these headwinds, investors can still find opportunities by exploring penny stocks—smaller or newer companies that may offer unique value propositions. While the term "penny stocks" might seem outdated, these investments continue to be relevant for those seeking potential growth and stability in...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Telia Company...

Fastenal Company ( NASDAQ:FAST ) came out with its quarterly results last week, and we wanted to see how the business...

Newell Brands (NWL) has drawn investor attention after recent share price moves, with the stock closing at $5.43. That places the company’s market value near $2.31 billion and is prompting fresh questions about valuation. See our latest analysis for Newell Brands. The recent 1 day share price return of 5.23% adds to a 90 day share price return of 25.40% and a year to date share price return of 45.97%, while the 5 year total shareholder return has declined 74.83%. This combination indicates...

A sharp escalation in U.S. and Iran tensions, wider strikes across the region, and an 11% weekly jump in Brent and WTI futures have quickly reshaped the risk and return trade off around oil and gas. When the Strait of Hormuz and broader Middle East supply routes face higher disruption risk, some companies exposed to this news may see new opportunities while others confront added uncertainty and cost. This article walks through three stocks from the Energy Sector, Oil & Gas Producers screener...

Legend Biotech (NasdaqGS:LEGN) is in focus after reporting that CARVYKTI® generated about US$657 million in net trade sales for the quarter ended June 30, 2026, based on figures provided by partner Janssen. See our latest analysis for Legend Biotech. Despite the CARVYKTI® sales update, Legend Biotech’s share price has been under pressure in the short term, with a 7 day share price return down 17.06% and a 30 day share price return down 31.97%, while the 1 year total shareholder return is down...

Clearway Energy has delivered a 56.6% total return over the past 5 years, yet its current checks still lean on the cheap side, which raises the question of whether the recent share price around US$33.77 is fully reflecting the underlying cash generation and risks. A 56.6% return over 5 years suggests Clearway Energy has already rewarded patient investors, so any further upside may depend on how much value is still not priced in. The build out of renewable and storage assets tied to long term...

In recent days, BYD has accelerated its global push with new model previews, an overhauled overseas brand structure, a planned European plant led by former Hungarian foreign minister Peter Szijjarto, and a multi-year advanced materials partnership with Covestro for vehicles, batteries, and energy storage. Together with rising interest in Chinese EVs in markets like Canada and growing plug-in hybrid traction in Southeast Asia, these moves highlight BYD’s effort to deepen its international...

Charter Communications stock has had a tough run over the last few years, yet its valuation checks currently lean cheap. This sets up a clear tension between the share price slide and what the broader metrics imply about value. Over the past 5 years, Charter Communications has declined about 81.5%, which means long term holders have seen a substantial erosion in market value. For today’s valuation, the key support is whether the core subscription and broadband cash flows can remain...

Enphase Energy stock is caught between mixed valuation signals, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to a premium to today’s price while market based multiples screen as more supportive, all against a five year share price record that has been heavily negative. Over the last 5 years, Enphase Energy has delivered a share price decline of 77.0%, which sets a cautious backdrop for any valuation case today. On the upside, new products such as the IQ9N...

In the days leading up to its 22 July 2026 earnings release, GE Vernova drew attention as analysts pointed to strong anticipated second‑quarter results supported by AI data center–driven power demand and a growing backlog in its Power and Electrification segments, even as the Wind business continued to face project delays and supply‑chain issues. An interesting angle is GE Vernova’s decision to commit US$11 billion to capital expenditure and R&D through 2028 to capture AI‑related power and...

UnitedHealth Group (UNH) is back in focus after reporting second quarter results that beat expectations on revenue and adjusted earnings, lifting full year profit guidance and sending the stock sharply higher. See our latest analysis for UnitedHealth Group. The latest jump in UnitedHealth Group’s share price comes on top of a 30.42% 90 day share price return and a 50.91% total shareholder return over the past year. This suggests momentum has rebuilt after the 2025 setback, and the recent...

In July 2026, Arovella Therapeutics announced a collaboration under which Charles River Laboratories International will provide GMP Next Generation Sequencing services for iNKT cell characterization and viral safety testing to support ALA-101, an off-the-shelf CAR-iNKT therapy targeting CD19+ B cell cancers. This partnership, combined with Charles River’s recent acquisition of NGS specialist Pathoquest, underscores its push into higher-value sequencing-based testing for cell and gene...

Lenivia launch puts Zoetis stock back on investors’ radar Zoetis (ZTS) has just rolled out Lenivia, a long acting monoclonal antibody therapy for canine osteoarthritis pain, offering up to three months of relief from a single injection in Canada and the EU. See our latest analysis for Zoetis. Despite the Lenivia launch and recent vaccine approvals in Europe, Zoetis has been under pressure, with the share price at $76.91 and the year to date share price return down 38.9%, while the 1 year...

Hudbay Minerals (TSX:HBM) has come under the spotlight after its share price fell 22.68% over the past month to close the latest session at CA$29.24, as investors look ahead to its July 29 earnings report. See our latest analysis for Hudbay Minerals. Over the past month, Hudbay Minerals’ 1 month share price return of down 28.21% and 1 day move of down 5.25% contrast with a 1 year total shareholder return of 117.34%. This signals fading short term momentum against a much stronger multi year...

Sunrise Energy Metals (ASX:SRL) is back in focus after fresh attention on its Sunrise project feasibility study and the Lockheed Martin option over early scandium output, set against rising interest in battery metals supply. See our latest analysis for Sunrise Energy Metals. Recent trading has been volatile, with Sunrise Energy Metals’ share price down 14.46% over the last day and 18.69% over the past month. The company still shows an 84.59% share price return year to date and a very large 1...

BigBear.ai recently expanded its generative AI platform for Department of War mission teams, adding new air-gapped hardware, flexible tenant setups, and both cloud-connected and fully local deployment options across classified environments. A key shift is the move from the Ask Sage brand to a refactored, model-agnostic BigBear.ai platform that lets agencies separate secure workspace licensing from their own “bring-your-own-model” procurement. Now we’ll examine how the new air-gapped,...

Lower fertilizer tariffs, potential trade policy shifts and closer regulatory attention on industry giants are reshaping the playing field for U.S. agricultural producers. For investors, that mix of lower input costs and fresh policy uncertainty can create both opportunity and risk across related stocks. This article focuses on three U.S. Agricultural Producers screener stocks that are directly exposed to the latest fertilizer and trade headlines, and explains how these developments might...

ASP Isotopes Inc. recently filed a shelf registration statement to issue up to US$106.08 million of common stock, covering 23,160,682 shares. This sizeable shelf registration gives the company flexibility to access equity capital quickly, which could shape how investors view its future financing plans. We will now examine how this sizeable shelf registration shapes ASP Isotopes' investment narrative and what it may imply for future capital needs. The future of work is here. Discover the 32...

Sony Group (TSE:6758) is reshaping its entertainment footprint, planning to end physical discs for new PlayStation games from January 2028 while continuing to put capital into AI, anime, and broader intellectual property. See our latest analysis for Sony Group. The recent announcements around digital only PlayStation games and fresh product launches like the AI driven RX10 V come as Sony Group’s 30 day share price return of 5.66% contrasts with a year to date share price decline of 14.88%...

Founder led companies sit at an interesting crossroads right now. With investors watching inflation, interest rates, energy prices and trade flows, many are looking for leaders who are directly invested in long term outcomes rather than short term targets. The Founder-Led Companies screener focuses on businesses where the original builder still has real skin in the game, aligning management decisions with shareholder interests through different market cycles. In this article, you will see...

Main Street Capital recently reported preliminary second-quarter 2026 results showing favorable distributable net investment income and its sixteenth consecutive quarterly increase in net asset value per share, driven primarily by fair value gains in its lower middle market and private loan portfolios. At the same time, analysts are increasingly cautious as income growth slows and management continues to raise regular and supplemental dividends, sharpening questions about the balance between...

Cybin, operating as Helus Pharma, has advanced its lead psychedelic candidate HLP003 into an ongoing Phase 3 trial for adjunctive treatment of major depressive disorder and recently raised about US$50,000,000 in an underwritten public offering to support its development programs. This combination of late-stage clinical progress and fresh funding highlights how Cybin is positioning HLP003 within the evolving landscape of interventional psychiatry for depression care. We’ll now explore how the...